Email not displaying correctly? View it in your browser     
Plant Form Header
$15M target for Medwell Capital

Medwell Securities, a wholly owned subsidiary of Medwell Capital Corp. (TSX-V: MWC), will provide strategic and financial advisory services to PlantForm, assisting the Company in raising up to $15 million.

“We’re pleased to be working with Medwell Securities to secure financing that will allow PlantForm to move our program forward through clinical trials,” said Don Stewart, President and CEO of PlantForm Corp.

“We believe that PlantForm has the potential to be the leader in the production of ‘generic’ biologic drugs, where there are a large group of drugs about to come off patent in the next few years,” said Kevin Giese, President and CEO of Medwell Capital. “The money being raised is intended to take PlantForm to a key value creation point, with clinical results from its lead compound for the treatment of cancer.”

In addition to strategic and financial services, Medwell has an advisory contract with PlantForm to assist with scientific and clinical advisory services.

Listen to a Medwell Capital webcast about biologic drugs and the PlantForm opportunity.

Scale-up complete, studies under way
Kentucky BioProcessing has successfully scaled-up PlantForm’s manufacturing process, producing three Good Manufacturing Practice (GMP) lots of our subsequent-entry-biologic trastuzumab. Animal safety and toxicology studies are now under way.

BioPartnering North America
PlantForm presented its investment case at the 9th annual BioPartnering North America conference in Vancouver in late February, generating interest within the West Coast investment community.

Industry news
Ontario to expand access to Herceptin
Breast cancer patient’s demand for equal access to the drug prompts policy change.

Japan approves Herceptin for gastric cancer
Therapy targets stomach cancers linked to high levels of the HER-2 protein, Bloomberg reports.

Samsung to enter biopharmaceutical market
Samsung diversifying with plans to manufacture biologics in a joint venture with Quintiles.


Join us online!
Get regular updates on our activities and industry news by following PlantForm on Twitter and LinkedIn:
                        
Spring 2011
PlantForm featured on CBC Radio’s World at Six
PlantForm earned national coverage in budget story on federal SR&ED tax credits. Hear the report.

Fighting cancer with tobacco
PlantForm has received media coverage in Germany, Japan and the United States, thanks to promotional efforts by the Ontario Ministry of Economic Development & Trade. Read the MEDT story.

Upcoming Events

2011 World Congress on Industrial Biotechnology & Bioprocessing
PlantForm CSO Dr. Chris Hall will be a presenter on the Protein Engineering and Screening Methods panel May 10. Visit PlantForm at the Bioenterprise booth at this event May 8-11 in Toronto.

Leading-edge plant science
The fourth international conference on Plant-Based Vaccines and Antibodies 2011: Plant Expression Systems for Recombinant Pharmacologics will include presentations by PlantForm’s Chief Scientific Officer, Dr. J. Christopher Hall, and Director of Research, Dr. Michael McLean.

Dr. Hall will speak about Purification of a therapeutic antibody from genetically modified plants using Protein A-oleosin oilbody technology. Dr. McLean will give a talk on Process development and preclinical analysis of plant-produced Herceptin.

The conference takes place in Porto, Portugal, June 8-10.



Management Team

Don Stewart, PhD
President & CEO

Ron Hosking, CA
Chief Financial Officer

Chris Hall, PhD
Chief Scientific Officer
PlantForm is a Canadian company focused on providing
low-cost therapeutic antibody drugs that fight cancer and other critical illnesses.

Our mailing address is:
1920 Yonge St, Suite 200
Toronto, Ontario
M4S 3E2  CANADA		 For more information, contact:
Don Stewart
President & CEO
416-452-7242